歐林生物(688319.SH):自主研發的幽門螺桿菌疫苗是在國內外已有經驗的基礎上對技術進行了升級換代
格隆匯5月4日丨有投資者向歐林生物(688319.SH)提問:請簡要介紹一下A羣鏈球菌疫苗和幽門螺桿菌疫苗的研發情況。
歐林生物回覆:這兩個疫苗品種目前都在臨牀前研究階段。A羣鏈球菌疫苗是公司2016年開始和澳大利亞格里菲斯大學合作研發,根據相關協議,公司擁有大中華區獨家的商業化權力。目前原研單位已經在加拿大開始了Ⅰ期臨牀試驗。公司也在同步推進該項目進度,準備結合加拿大Ⅰ期臨牀試驗數據,進行後續國內的臨牀試驗申報。公司自主研發的幽門螺桿菌疫苗是在國內外已有經驗的基礎上對技術進行了升級換代,公司擁有完全的自主知識產權,未來將根據經營計劃有序推動該項目研發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.